Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2014-06-01
|
Series: | Acta Facultatis Medicae Naissensis |
Subjects: | |
Online Access: | http://www.degruyter.com/view/j/afmnai.2014.31.issue-2/afmnai-2014-0010/afmnai-2014-0010.xml?format=INT |
id |
doaj-4bfb41010f0e4e25a01cf9e8d24fc48d |
---|---|
record_format |
Article |
spelling |
doaj-4bfb41010f0e4e25a01cf9e8d24fc48d2020-11-25T01:05:22ZengSciendoActa Facultatis Medicae Naissensis2217-25212014-06-01312879410.2478/afmnai-2014-0010afmnai-2014-0010Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical DillemasPejčić Ivica0Vrbić Svetislav1Todorović Mirjana2Petković Ivan3Balić Mirjana4Stanković Ana5Clinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaMetastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques and procedures, there is no improvement in efficacy (efficiency) of indentifying the primary site of disseminated disease. That is why a diagnostic procedure should be rational and should include the basic diagnostic examination (analyses) with the aim to define biological and clinical characteristics of diagnosed disease, as well as an optimal therapeutic approach. Although the overall prognosis of the majority of these patients is poor, it is possible, nowadays, to distinguish the subgroups of patients with favorable prognosis. Results of new basic research, better understanding of pathogenesis at the molecular level and introduction of new drugs through clinical trials suggest an advance in this disease treatment and outcome.http://www.degruyter.com/view/j/afmnai.2014.31.issue-2/afmnai-2014-0010/afmnai-2014-0010.xml?format=INTmalignant tumormetastaseschemotherapyCUP |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pejčić Ivica Vrbić Svetislav Todorović Mirjana Petković Ivan Balić Mirjana Stanković Ana |
spellingShingle |
Pejčić Ivica Vrbić Svetislav Todorović Mirjana Petković Ivan Balić Mirjana Stanković Ana Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas Acta Facultatis Medicae Naissensis malignant tumor metastases chemotherapy CUP |
author_facet |
Pejčić Ivica Vrbić Svetislav Todorović Mirjana Petković Ivan Balić Mirjana Stanković Ana |
author_sort |
Pejčić Ivica |
title |
Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas |
title_short |
Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas |
title_full |
Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas |
title_fullStr |
Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas |
title_full_unstemmed |
Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas |
title_sort |
cancer of unknown primary site syndrome‐cup syndrome - diagnostic and therapeutical dillemas |
publisher |
Sciendo |
series |
Acta Facultatis Medicae Naissensis |
issn |
2217-2521 |
publishDate |
2014-06-01 |
description |
Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques and procedures, there is no improvement in efficacy (efficiency) of indentifying the primary site of disseminated disease. That is why a diagnostic procedure should be rational and should include the basic diagnostic examination (analyses) with the aim to define biological and clinical characteristics of diagnosed disease, as well as an optimal therapeutic approach. Although the overall prognosis of the majority of these patients is poor, it is possible, nowadays, to distinguish the subgroups of patients with favorable prognosis. Results of new basic research, better understanding of pathogenesis at the molecular level and introduction of new drugs through clinical trials suggest an advance in this disease treatment and outcome. |
topic |
malignant tumor metastases chemotherapy CUP |
url |
http://www.degruyter.com/view/j/afmnai.2014.31.issue-2/afmnai-2014-0010/afmnai-2014-0010.xml?format=INT |
work_keys_str_mv |
AT pejcicivica cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas AT vrbicsvetislav cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas AT todorovicmirjana cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas AT petkovicivan cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas AT balicmirjana cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas AT stankovicana cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas |
_version_ |
1725194891611340800 |